Can Wegovy Cause Vision Changes? What the Evidence Says

Why do some Wegovy users notice changes to their vision?

The most common explanation is not a direct drug effect on eye tissue. When semaglutide reduces appetite and calorie intake, blood-glucose levels fall, sometimes fairly quickly. The lens of the eye is sensitive to changes in fluid balance, and as glucose levels shift, the lens can temporarily swell or shrink, causing mild blurring. This usually settles within a few weeks as the body acclimates. If you wear glasses or contact lenses, your prescription may feel slightly off during this period; getting a new prescription straight away is worth pausing on, since the effect tends to be short-lived.

There is a separate, more clinically significant concern for people with diabetes. The Wegovy SmPC and the NHS patient information for semaglutide note that diabetic retinopathy complications (including haemorrhage and reduced vision) have been reported, particularly in people with type 2 diabetes who experience a rapid fall in blood sugar at the start of treatment. The mechanism is thought to involve sudden improvement in glycaemic control exposing fragile retinal blood vessels to changed conditions. This risk profile is one reason semaglutide's clinical background matters so much in the prescribing decision.

For most people starting Wegovy for weight management who do not have diabetes or retinopathy, serious eye complications are not expected. Still, awareness of what to watch for is a reasonable part of starting any new treatment.

Which vision symptoms should prompt immediate medical attention?

Mild, temporary blurring that resolves on its own is very different from the symptoms that need urgent assessment. Contact a doctor or NHS 111 the same day (do not wait for a routine review) if you experience any of the following: sudden loss of vision in one or both eyes, floaters or flashing lights appearing abruptly, a dark shadow or curtain across part of your visual field, or any pain behind the eye. These are not typical GLP-1 side effects; they are warning signs that warrant same-day evaluation regardless of what medicine you are taking.

Persistent blurring that does not settle after a few weeks, or gradual worsening of vision at any point during treatment, also deserves attention. The fuller picture of how Wegovy may affect vision covers the retinopathy concern in more detail, but the practical rule is straightforward: if a vision change worries you or does not resolve, tell a clinician. The MHRA's Yellow Card scheme also allows patients to report suspected side effects directly, which contributes to ongoing safety monitoring of medicines like semaglutide.

People with a known diagnosis of diabetic retinopathy should specifically discuss this with their prescriber before starting treatment. Closer monitoring, or a different approach, may be appropriate.

Does semaglutide affect vision in people without diabetes?

The evidence here is reassuring but not absolute. The large STEP 1 trial (which studied semaglutide 2.4mg in adults with obesity and no diabetes) did not flag retinopathy as a safety signal in that population. The retinopathy reports have emerged predominantly from the diabetes setting, where background retinal vulnerability already exists. That context matters when weighing what vision-related information applies to you.

There is a separate area of emerging interest: reports of a rare condition called non-arteritic anterior ischaemic optic neuropathy (NAION) appearing in some GLP-1 users, discussed in research correspondence published in 2024. The evidence for a causal link is preliminary and contested; the MHRA was monitoring this signal as of mid-2026. This is not grounds for alarm, but it is a reason that honest, thorough prescribing matters. Our clinical team stays current with evolving safety communications, and you can read more about semaglutide's broader effects on vision as this evidence develops.

Semaglutide can also produce other unexpected sensory changes. Some people notice shifts in taste perception during treatment; if that is a concern, semaglutide and taste changes covers what is known. Similarly, changes to facial appearance sometimes come up alongside weight loss. These reflect how interconnected the body's systems are during significant weight change.

What should you tell your prescriber about your eyes before starting Wegovy?

Before beginning treatment, it is worth telling your prescribing clinician if you have an existing diagnosis of diabetic retinopathy, have had any eye surgery, or are currently under the care of an ophthalmologist. This lets the prescriber factor those details into their assessment and, where appropriate, suggest that your eye specialist is kept in the loop.

It is also worth mentioning any history of sudden vision loss, as this may be relevant to assessing NAION risk. Honest disclosure at the consultation stage is what makes clinical review meaningful, it is why Wegovy is a prescription-only medicine requiring individual assessment, not something to obtain without one.

Storing your pen properly is a small but practical part of managing treatment well. The pen should be kept in the refrigerator between 2°C and 8°C; many people find it easiest to keep it on the shelf in the fridge door, close to hand without risk of freezing. Exact guidance on room-temperature windows if you need to travel is in the Patient Information Leaflet supplied with your medicine.

If you are considering Wegovy and have questions about your eye health or other aspects of your medical history, checking your eligibility through a free consultation is the right first step. If you already take Wegovy and have concerns about how your vision is changing, speak to a clinician today. You can also find information about other unexpected effects of semaglutide to help you know what is typical and what is not.